Market research
NMRD Nemaura Medical Inc
PINK USD Healthcare
Latest close
As of 20 Oct 2026
Test a moving-average rule with historical data.
Market facts
- Market cap
- 4K
- P/E ratio
- Not available
- Analyst target
- 1.5
- Dividend yield
- Not available
- Beta
- -105.12
Profile
Instrument facts
- Exchange
- PINK
- Currency
- USD
- Sector
- Healthcare
- Industry
- Medical Devices
- ISIN
- Not available
- Market cap
- 4K
- P/E ratio
- Not available
- Analyst target
- 1.5
- Dividend yield
- Not available
- Beta
- -105.12
About
About Nemaura Medical Inc
Nemaura Medical Inc., a medical technology company, manufactures continuous glucose monitoring system in the United States. It offers sugarBEAT, a non-invasive continuous glucose monitoring device for use by persons with Type I and Type II diabetes, as well as screen pre-diabetic patients. The company also offers proBEAT, a wellness guidance notes, that provide prompts and educate users on factors affecting blood sugar profiles, as well as conducts diabetes prevention and reversal programs. Nemaura Medical Inc. was founded in 2009 and is based in New York, New York.
Research context
Nemaura Medical Inc appears in PyInvesting’s US Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- USD
- Sector
- Healthcare
- Industry
- Medical Devices
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the NMRD discussion.
5 years, 7 months ago
Nemaura Medical Inc is currently in a long term uptrend where the price is trading 31.9% above its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
Nemaura Medical Inc's total revenue sank by nan% to $0 since the same quarter in the previous year.
Its net income has dropped by 225.1% to $-1M since the same quarter in the previous year.
Finally, its free cash flow fell by 186.6% to $-2M since the same quarter in the previous year.
Based on the above factors, Nemaura Medical Inc gets an overall score of 2/5.